RecruitingPhase 2NCT06462547

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

The ADAPT Study: An Open-label, Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

Sponsor

Inozyme Pharma

Enrollment

200 participants

Start Date

Jun 19, 2024

Study Type

INTERVENTIONAL

Conditions

Arterial calcification Pseudoxanthoma Elasticum Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency Gene Mutations Autosomal Recessive Hypophosphatemic Rickets Type 2

Summary

The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.

Eligibility

Min Age: 1 Year

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INZ-701 for people with arterial calcification, autosomal recessive hypophosphatemic rickets type 2, and other related conditions. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 1 Year and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINZ-701

INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).